tradingkey.logo

BRIEF-Northstrive Biosciences, Subsidiary of PMGC Holdings, Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

ReutersFeb 4, 2025 2:27 PM

- PMGC Holdings Inc ELAB.O:

  • PMGC UNIT, NORTHSTRIVE, SAYS PREPARING FOR FDA INVESTIGATIONAL NEW DRUG FILING FOR EL-22

  • NORTHSTRIVE - ANTICIPATES TYPE B PRE-IND MEETING WITH FDA IN Q2 2025

Source text: ID:nGNX8gZXxS

Further company coverage: ELAB.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI